Responses
Quality of Life
Evaluation of the Hematologic Safety of Same Day Versus Standard Administration (24- to 72-Hour Delay) of Pegfilgrastim in Gynecology Oncology Patients Undergoing Cytotoxic Chemotherapy
Compose a Response to This Article
Other responses
No responses have been published for this article.